Bone loss associated with long-term use of depot medroxyprogesterone acetate.
Hong Kong Med J
; 11(6): 491-5, 2005 Dec.
Article
en En
| MEDLINE
| ID: mdl-16340026
ABSTRACT
On 17 November 2004, the United States Food and Drug Administration issued a black box warning on the long-term use of depot medroxyprogesterone acetate stating that bone loss might be irreversible with use of more than 2 years. Despite the seriousness of such a safety warning, the Food and Drug Administration provided no clinical recommendations. Various professional bodies have made different recommendations on the management of women prescribing such long-term injections but there is no consensus on the best practice. Thus individual institutions need to revise service protocols. The Health Services Subcommittee of the Family Planning Association of Hong Kong has reviewed the scientific evidence from international and local studies and made its recommendations in a meeting held on 1 March 2005. This article aimed to share our opinion with other medical professionals in Hong Kong.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Densidad Ósea
/
Acetato de Medroxiprogesterona
/
Anticonceptivos Femeninos
/
Anticonceptivos Hormonales Orales
/
Preparaciones de Acción Retardada
Tipo de estudio:
Etiology_studies
/
Guideline
/
Risk_factors_studies
Límite:
Adolescent
/
Adult
/
Female
/
Humans
País/Región como asunto:
America do norte
/
Asia
Idioma:
En
Revista:
Hong Kong Med J
Asunto de la revista:
MEDICINA
Año:
2005
Tipo del documento:
Article
País de afiliación:
Hong Kong